文献速递白血病MDS 与骨髓增殖性肿瘤

急性髓系白血病与骨髓增生异常综合征中KMT2A部分串联重复的等位基因复杂性

Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2022-01-01

该研究通过靶向DNA二代测序(NGS)识别94例携带KMT2A部分串联重复(KMT2A-PTD)的患者,发现16%(15/94)存在复杂继发事件,包括拷贝中性杂合性缺失和涉及KMT2A-PTD等位的选择性获得。高拷贝数提示的复杂性在AML中较MDS显著富集,并与更高的RNA表达相关;在连续样本中,复杂性与复发和继发性转化相关。

要点

  • 16%(15/94)的KMT2A-PTD患者存在复杂继发事件,包括拷贝中性杂合性缺失和选择性获得。
  • 高拷贝数提示的复杂性在AML中较MDS显著富集,并与更高的RNA表达相关。
  • 连续样本中,复杂性与复发和继发性转化相关。

核心结论

  • 研究证明KMT2A-PTD可通过多种机制发生继发性遗传事件,这些事件可能通过驱动受累等位基因表达增加而与髓系疾病进展相关。

研究设计与样本

  • 研究采用靶向DNA二代测序(NGS)识别94例携带KMT2A-PTD的急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者。

主要发现

  • 16%(15/94)的患者存在复杂继发事件,包括拷贝中性杂合性缺失和涉及KMT2A-PTD等位的选择性获得。
  • 高拷贝数提示的复杂性在AML中较MDS显著富集,并与更高的RNA表达相关。
  • 在连续样本中,复杂性与复发和继发性转化相关。

关键数值与推荐

  • KMT2A-PTD是AML和MDS的不良风险因素、潜在治疗靶点和可测量残留病的有吸引力的标志物。

临床怎么用

  • 研究提供了将KMT2A-PTD的定量和等位基因评估整合到靶向DNA NGS中的方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KMT2A partial tandem duplication (KMT2A-PTD) is an adverse risk factor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a potential therapeutic target, and an attractive marker of measurable residual disease. High initial KMT2A-PTD RNA levels have been linked to poor prognosis, but mechanisms regulating KMT2A-PTD expression are not well understood. Although KMT2A-PTD has been reported to affect only a single allele, it has been theorized but not proven that genomic gains of a monoallelic KMT2A-PTD may occur, thereby potentially driving high expression and disease progression. In this study, we identified 94 patients with KMT2A-PTDs using targeted DNA next-generation sequencing (NGS) and found that 16% (15/94) had complex secondary events, including copy-neutral loss of heterozygosity and selective gain involving the KMT2A-PTD allele. High copy numbers indicating complexity were significantly enriched in AML vs MDS and correlated with higher RNA expression. Moreover, in serial samples, complexity was associated with relapse and secondary transformation. Taken together, we provide approaches to integrate quantitative and allelic assessment of KMT2A-PTDs into targeted DNA NGS and demonstrate that secondary genetic events occur in KMT2A-PTD by multiple mechanisms that may be linked to myeloid disease progression by driving increased expression from the affected allele.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tsai HK, Gibson CJ, Murdock HM, et al. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. Blood Adv. 2022. PMID: 35584376. doi:10.1182/bloodadvances.2022007613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。